Camizestrant: First Approval

doi:10.1007/s40265-026-02385-z

2026-09-25

PRE

Arnold Lee *

DOI：10.1007/s40265-026-02385-z

原文链接

原文求助

摘要

En 中文

卡米泽斯特（Etcamah®）是一种口服可用的强效选择性雌激素受体降解剂（SERD）和完全雌激素受体（ER）α拮抗剂，由阿斯利康公司开发用于治疗乳腺癌。该药物于2025年5月在阿联酋首次获得批准。截至本文撰写时，该药物已相继在沙特阿拉伯、日本、欧盟、加拿大、英国和美国获得批准。对于携带可检测ESR1突变的ER阳性、HER2阴性乳腺癌患者，在继续使用相同CDK4/6抑制剂的同时换用卡米泽斯特，与继续使用芳香化酶抑制剂联合CDK4/6抑制剂治疗相比，显著延长了无进展生存期。本文总结了卡米泽斯特在开发过程中的关键里程碑，这些里程碑促成了其首次批准用于治疗携带ESR1基因突变（该突变在一线激素治疗期间出现）的局部晚期或转移性激素受体阳性（HR+）、HER2阴性乳腺癌成人患者，联合CDK4/6抑制剂。

期刊

Drugs

IF:

14.4

论文数:

8.4K

被引数:

2.3W

机构

暂无机构信息

引用论文

Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†转移性乳腺癌: ESMO诊断、治疗和随访临床实践指南 †

Annals of Oncology

IF65.4

2026-05-29

PREAI

E. de Azambuja; C.H. Barrios; R. Bartsch; G. Curigliano; R. Dent; A. Gennari; S. Loi; S. Paluch-Shimon; B. Pistilli; C. Saura; P. Schmid; T. Spanic; M. Toi; S.M. Tolaney; N. Harbeck

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

NATURE COMMUNICATIONS

IF15.7

2016-05-13

270

OAAI

Spoerke, Jill M.; Gendreau, Steven; Walter, Kimberly; Qiu, Jiaheng; Wilson, Timothy R.; Savage, Heidi; Aimi, Junko; Derynck, Mika K.; Chen, Meng; Chan, Iris T.; Amler, Lukas C.; Hampton, Garret M.; Johnston, Stephen; Krop, Ian; Schmid, Peter; Lackner, Mark R.

A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results 在ER阳性，HER2-negative晚期乳腺癌女性中，下一代口服SERD camizestrant的I期剂量递增和扩展试验: SERENA-1单药治疗结果

ANNALS OF ONCOLOGY

IF65.4

2024-08-01

OAAI

Hamilton, E.; Oliveira, M.; Turner, N.; Garcia-Corbacho, J.; Hernando, C.; Ciruelos, E. M.; Kabos, P.; Ruiz-Borrego, M.; Armstrong, A.; Patel, M. R.; Vaklavas, C.; Twelves, C.; Boni, V.; Incorvati, J.; Brier, T.; Gibbons, L.; Klinowska, T.; Lindemann, J. P. O.; Morrow, C. J.; Sykes, A.; Baird, R. D.

Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status

Drug Design, Development and Therapy

IF0

2022-09-01

OAAI

Teesha Downton; Fiona Zhou; Davendra Segara; Rinath Jeselsohn; Elgene Lim

Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2020-09-10

PREAI

Scott, James S.; Moss, Thomas A.; Balazs, Amber; Barlaam, Bernard; Breed, Jason; Carbajo, Rodrigo J.; Chiarparin, Elisabetta; Davey, Paul R. J.; Delpuech, Oona; Fawell, Stephen; Fisher, David, I; Gagrica, Sladjana; Gangl, Eric T.; Grebe, Tyler; Greenwood, Ryan D.; Hande, Sudhir; Hatoum-Mokdad, Holia; Herlihy, Kara; Hughes, Samantha; Hunt, Thomas A.; Hoan Huynh; Janbon, Sophie L. M.; Johnson, Tony; Kavanagh, Stefan; Klinowska, Teresa; Lawson, Mandy; Lister, Andrew S.; Marden, Stacey; McGinnity, Dermot F.; Morrow, Christopher J.; Nissink, J. Willem M.; O'Donovan, Daniel H.; Peng, Bo; Polanski, Radoslaw; Stead, Darren S.; Stokes, Stephen; Thakur, Kumar; Throner, Scott R.; Tucker, Michael J.; Varnes, Jeffrey; Wang, Haixia; Wilson, David M.; Wu, Dedong; Wu, Ye; Yang, Bin; Yang, Wenzhan

Abstract PS1-10-28: Phase 1/2a trial of new generation PARP1-selective inhibitor saruparib + next generation selective ER degrader (SERD) camizestrant in patients (pts) with advanced/relapsed ER+/HER2-negative or low (HER2−) breast cancer (PETRA Module 6)新一代PARP1选择性抑制剂saruparib与下一代选择性ER降解剂（SERD）camizestrant联合治疗晚期/复发性ER+/HER2阴性或低表达（HER2−）乳腺癌患者的1/2a期临床试验（PETRA Module 6）[摘要编号PS1-10-28]

Clinical Cancer Research

IF0

2026-02-17

PREAI

Yap,T. A.; Yonemori,K.; Li,W.; Kitano,S.; Lynce,F.; Sharp,A.; Falcón,A.; Garcia-Corbacho,J.; Baird,R. D.; Balmaña,J.; Nanda,S.; Song,I.; Sugibayashi,K.; Womersley,L.; Squatrito,M.; Gangl,E.; Milenkova,T.; Luen,S. J.

Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1

Clinical Cancer Research

IF0

2025-10-15

PREAI

Baird,Richard D.; Bermejo de las Heras,Begoña; Ruiz-Borrego,Manuel; Vaklavas,Christos; Moreno,Irene; Oliveira,Mafalda; Armstrong,Anne; Turner,Nicholas; Incorvati,Jason; Twelves,Chris; Ciruelos,Eva; Hamilton,Erika; Patel,Manish R.; Kabos,Peter; Ciardullo,Carmela; Klinowska,Teresa; Lindemann,Justin P.O.; Mathewson,Alastair M.; Morrow,Christopher J.; Sykes,Andy; Yang,Jincheng; Zhang,Bairu; Victoria,Ivan

Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study 在雌激素受体阳性、人表皮生长因子受体2阴性原发性乳腺癌的绝经后女性中卡米泽斯特抗治疗的药效学：来自随机、术前SERENA-3研究的结果

Journal of Clinical Oncology

IF0

2026-03-20

PREAI

Robertson,John F.R.; Gogitidze,Teimuraz; Katashvili,Zaza; Rocha,Juan Enrique Bargalló; Arkania,Ekaterine; Moppett,Iain; Cheung,Kwok-Leung; Nemsadze,Gia; Ajimi,Maxine; Klinowska,Teresa; Lindemann,Justin P.O.; Mathewson,Alastair; Morrow,Christopher J.; Nikolaou,Myria; Scaltriti,Maurizio; Sykes,Andy; Dzagnidze,Giorgi

Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial Camizestrant，一种下一代口服SERD，与fulvestrant对比用于绝经后雌激素受体阳性、HER2阴性晚期乳腺癌患者（SERENA-2）：一项多剂量、开放标签、随机化、II期临床试验

The Lancet Oncology

IF0

2024-11-01

PREAI

Mafalda Oliveira; Denys Pominchuk; Zbigniew Nowecki; Erika Hamilton; Yaroslav Kulyaba; Timur Andabekov; Yevhen Hotko; Tamar Melkadze; Gia Nemsadze; Patrick Neven; Vladimir Vladimirov; Claudio Zamagni; Hannelore Denys; Frédéric Forget; Zsolt Horvath; Alfiya Nesterova; Maxine Ajimi; Bistra Kirova; Teresa Klinowska; Justin P O Lindemann; Delphine Lissa; Alastair Mathewson; Christopher J Morrow; Zuzana Traugottova; Ruaan van Zyl; Ekaterine Arkania

Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1☆Camizestrant联合capivasertib治疗ER阳性，HER2-negative晚期乳腺癌的女性: SERENA-1 ☆ 的结果

ESMO Open

IF8.3

2026-01-21

OAAI

C. Vaklavas; M. Oliveira; A.C. Armstrong; I. Moreno; C. Twelves; I. Victoria Ruiz; B. Bermejo de las Heras; T. Brier; C. Ciardullo; L. Gibbons; T. Jack; T. Klinowska; J.P.O. Lindemann; A.M. Mathewson; R. Maudsley; C.J. Morrow; A. Sykes; R.D. Baird

查看更多内容